Target Name: KCNH6
NCBI ID: G81033
Other Name(s): ERG-2 | Ether-a-go-go related gene potassium channel 2 | hERG2 | Potassium voltage-gated channel subfamily H member 6 | hERG-2 | potassium voltage-gated channel, subfamily H (eag-related), member 6 | Voltage-gated potassium channel subunit Kv11.2 | Potassium voltage-gated channel subfamily H member 6 (isoform 1) | eag-related gene member 2 | voltage-gated potassium channel subunit Kv11.2 | Ether-a-go-go-related protein 2 | HERG2 | KCNH6 variant 1 | KCNH6_HUMAN | potassium channel, voltage gated eag related subfamily H, member 6 | ether-a-go-go-related protein 2 | ERG2 | Potassium voltage-gated channel subfamily H member 6, transcript variant 1 | potassium voltage-gated channel subfamily H member 6 | Eag related protein 2 | Eag-related protein 2 | Kv11.2 | Ether-a-go-go-related gene potassium channel 2

Understanding KCNH6: Key Enzyme in The Citric Acid Cycle

KCNH6 (Ketone-Citrate Reductase) is a protein that is expressed in various tissues throughout the body. It is a key enzyme in the citric acid cycle, also known as the Krebs cycle or tricarboxylic acid (TCA) cycle, which is a central metabolic pathway that generates energy in the form of ATP from glucose.

The KCNH6 enzyme is critical for the production of ketones, which are molecules that are produced when the body breaks down fats and proteins to use as energy. Ketones are particularly important for maintaining the proper functioning of the brain and nervous system, as they can help to protect against the effects of certain diseases.

Research has also shown that KCNH6 is involved in the production of other important molecules, including carbon dioxide and water. It is a potential drug target for various diseases, including cancer, and has also been identified as a potential biomarker for certain conditions.

One of the key challenges in studying KCNH6 is its complex structure. Unlike many other proteins, which have a single amino acid sequence per molecule, KCNH6 has a complex structure that includes multiple domains. These domains include an N-terminus, a catalytic core, and a C-terminus.

The N-terminus of KCNH6 contains a unique sequence that is conserved in many different organisms. This sequence is thought to be involved in the protein's stability and functions as an enzyme. The catalytic core of KCNH6 is the part of the protein that is responsible for catalyzing chemical reactions. This core is composed of multiple beta-helices, which are regions of the protein that are known for their ability to fold in specific shapes and to interact with other molecules.

The C-terminus of KCNH6 contains a series of conserved amino acids that are involved in the protein's stability and functions as an enzyme. These amino acids include Asp, Asn, Glu, and Lys.

KCNH6 has been shown to play a key role in the production of ketones from fats and proteins. Studies have shown that when the body breaks down fats and proteins to use as energy, it produces ketones as byproducts. These ketones can then be used by the body to provide energy and to help regulate various physiological processes.

In addition to its role in ketone production, KCNH6 has also been shown to play a key role in the production of other important molecules, including carbon dioxide and water. These molecules are produced by the body as a byproduct of the citric acid cycle, and they are important for various physiological processes, including the regulation of pH and the production of energy.

KCNH6 is also a potential drug target for various diseases, including cancer. Many studies have shown that inhibiting the activity of KCNH6 can have a beneficial effect on the growth and spread of cancer cells. This is because when cancer cells are broken down by the body, they produce large amounts of ketones as byproducts. By inhibiting the production of ketones, cancer cells may be less able to provide energy for their growth and expansion.

In addition to its potential as a drug target, KCNH6 has also been identified as a potential biomarker for certain conditions. For example, some studies have shown that levels of KCNH6 have been elevated in the blood of people with certain types of cancer, which suggests that they may be able to serve as a biomarker for the disease.

Overall, KCNH6 is a complex protein that is involved in various physiological processes in the body. It is a potential drug target for various diseases, including cancer, and has also been identified as a potential biomarker for these conditions. Further research is needed to fully understand the role of KCNH6 in the body and to develop new treatments for diseases that are caused by its activity.

Protein Name: Potassium Voltage-gated Channel Subfamily H Member 6

Functions: Pore-forming (alpha) subunit of voltage-gated potassium channel. Elicits a slowly activating, rectifying current (By similarity). Channel properties may be modulated by cAMP and subunit assembly

More Common Targets

KCNH7 | KCNH7-AS1 | KCNH8 | KCNIP1 | KCNIP1-OT1 | KCNIP2 | KCNIP3 | KCNIP4 | KCNIP4-IT1 | KCNJ1 | KCNJ10 | KCNJ11 | KCNJ12 | KCNJ13 | KCNJ14 | KCNJ15 | KCNJ16 | KCNJ18 | KCNJ2 | KCNJ2-AS1 | KCNJ3 | KCNJ4 | KCNJ5 | KCNJ5-AS1 | KCNJ6 | KCNJ8 | KCNJ9 | KCNK1 | KCNK10 | KCNK12 | KCNK13 | KCNK15 | KCNK15-AS1 | KCNK16 | KCNK17 | KCNK18 | KCNK2 | KCNK3 | KCNK4 | KCNK5 | KCNK6 | KCNK7 | KCNK9 | KCNMA1 | KCNMB1 | KCNMB2 | KCNMB2-AS1 | KCNMB3 | KCNMB4 | KCNN1 | KCNN2 | KCNN3 | KCNN4 | KCNQ Channels (K(v) 7) | KCNQ1 | KCNQ1DN | KCNQ1OT1 | KCNQ2 | KCNQ3 | KCNQ4 | KCNQ5 | KCNQ5-AS1 | KCNQ5-IT1 | KCNRG | KCNS1 | KCNS2 | KCNS3 | KCNT1 | KCNT2 | KCNU1 | KCNV1 | KCNV2 | KCP | KCTD1 | KCTD10 | KCTD11 | KCTD12 | KCTD13 | KCTD13-DT | KCTD14 | KCTD15 | KCTD16 | KCTD17 | KCTD18 | KCTD19 | KCTD2 | KCTD20 | KCTD21 | KCTD21-AS1 | KCTD3 | KCTD4 | KCTD5 | KCTD5P1 | KCTD6 | KCTD7 | KCTD8 | KCTD9 | KDELR1 | KDELR2 | KDELR3